基于改良型痘苗病毒安卡拉株载体的新型流感疫苗研究进展

摘要

Influenza,caused by influenza virus,is a respiratory infectious disease with a serious hazard to human health.Prevention of influenza through vaccine development is the most effective strategy.It is important to build a rapid response platform for research and production of influenza vaccine.As virus vectors,live vaccine provides a new prevention and treatment way for infectious disease.Modified vaccinia virus Ankara(MVA) is a replication-deficient viral vector that is safe and can encode one or more foreign antigens and induce humoral and cellular immune response.MVA holds great promise as a vaccine platform.In this review,we discuss the use of MVA for vaccine development against influenza virus.%流感是由流感病毒引起的一种严重危害公众健康的呼吸道传染病,已引起全球的高度关注,接种疫苗是预防流感最有效的措施.当前,建立快速流感疫苗研发生产平台对于流感的预防与控制至关重要.以病毒为载体的活疫苗为感染性疾病的防控提供了新的手段.改良型痘苗病毒安卡拉株(Modified Vaccinia virus Ankara,MVA)是一种复制缺陷型病毒载体.MVA能够同时容纳并表达多个外源抗原、诱导较好的体液和细胞免疫应答并具备良好的安全性,具有成为理想疫苗载体的潜力.本文就MVA载体在流感疫苗研究中的应用做一综述.